Opioid drugs are highly addictive and their abuse has a strong genetic load. Dopamine-glutamate interactions are hypothesized to be important for regulating neural systems central for addiction vulnerability. Balanced dopamine-glutamate interaction is mediated through several functional associations, including a physical link between discs, large homolog 4 (Drosophila) (DLG4, PSD-95) and dopamine receptor 1 (DRD1) within the postsynaptic density to regulate DRD1 trafficking. To address whether genetic associations with heroin abuse exist in relation to dopamine and glutamate and their potential interactions, we evaluated singlenucleotide polymorphisms of key genes within these systems in three populations of opiate abusers and controls, totaling 489 individuals from Europe and the United States. Despite significant differences in racial makeup of the separate samples, polymorphisms of DRD1 and DLG4 were found to be associated with opiate abuse. In addition, a strong gene-gene interaction between homer 1 homolog (Drosophila) (HOMER1) and DRD1 was predicted to occur in Caucasian subjects. This interaction was further analyzed by evaluating DRD1 genotype in relation to HOMER1b/c protein expression in postmortem tissue from a subset of Caucasian subjects. DRD1 rs265973 genotype correlated with HOMER1b/c levels in the striatum, but not cortex or amygdala; the correlation was inversed in opiate abusers as compared with controls. Cumulatively, these results support the hypothesis that there may be significant, genetically influenced interactions between glutamatergic and dopaminergic pathways in opiate abusers.
INTRODUCTION
Opioid drugs are of critical medical importance being potent analgesics, but their nonmedical use and abuse has increased worldwide, 1 and is associated with high mortality and morbidity. 2, 3 In addition to being highly addictive, opiate abuse has a strong genetic component with family, twin and adoption studies showing that genetic factors account for at least 40-60% of the overall vulnerability for heroin abuse. 4 Genetic associations have been documented between polymorphisms of opioidrelated genes and heroin abuse, [5] [6] [7] [8] but limited information exists about the potential relevance of other neurobiological systems in relation to genetic risk. Neurobiological theories have predominantly posited maladaptions of dopamine and glutamate neurotransmission, and their interaction, as critical for addiction vulnerability, as these neurotransmitters are strongly linked to reward, goal-directed action as well as habitual and compulsive behaviors that characterize addictive disorders. 9 Moreover, such behaviors are dependent on the integrity of the striatum, a brain region with prominent interactions between the dopaminergic and glutamatergic systems.
At a molecular level, balanced dopamine-glutamate interaction is mediated through functional interactions between dopamine D1 receptor (DRD1) and the N-methyl-D-aspartate (NMDA) glutamate receptors in postsynaptic neurons. DRD1 activation enhances NMDA receptor activity and induces rapid trafficking of intracellular NMDA receptors to the postsynaptic density. Postsynaptic density protein 95 (PSD-95, DLG4) interacts with NMDA receptors via NR2 subunits and may help to localize these receptors to the synapse. 10, 11 PSD-95 also interacts with DRD1 via the N-terminus of PSD-95 and the C-terminus of DRD1 to regulate DRD1 trafficking. 12 In addition to PSD-95, HOMER proteins (HOMER1-3) are also present at the postsynaptic density and have a critical role in glutamatergic transmission and also complex with PSD-95 by the Shank proteins. [13] [14] [15] Animal models have provided significant evidence in strong support of a role of HOMER and PSD-95 proteins in addiction disorders, [16] [17] [18] but no study has yet evaluated genetic variants in these genes in relation to opiate abuse. Moreover, despite the prevailing hypotheses regarding aberrant striatal synaptic plasticity and disturbance of HOMER and PSD-95 in addiction disorders, no information is available about their expression in the human striatum of drug abusers.
To obtain insights regarding DRD1 and postsynaptic glutamatergic genes directly in the human brain, we evaluated genetic associations in various heroin abuse populations and measured expression of the genes within postmortem striatal specimens. The findings reveal that DLG4 and DRD1 are associated with opiate abuse. In addition, there is evidence of a gene-gene interaction between homer homolog 1 (Drosophila) (HOMER1) and DRD1 with heroin abuse highlighting a potential disturbance between glutamatergic and DRD1 pathways.
MATERIALS AND METHODS Subjects
Three heroin/opiate abuse populations were used for this study. The first consisted of human brain samples from a predominant heroin abuse postmortem collection consisting of Caucasian Swedish and Hungarian subjects that has been previously described. 5 Briefly, these subjects were collected at the National Institute of Forensic Medicine, Karolinska Institutet, Stockholm, Sweden, as well as from the Department of Forensic Medicine at Semmelweis University, Hungary. We studied 127 Caucasian subjects: 46 controls (36 men, 10 women; average age 37.2 ± 14.4), which had negative blood toxicology for opiates and other illicit substances and 81 heroin users (67 men, 14 women; average age 25.7 ± 5.4) with cause of death identified as heroin intoxication (blood and urine toxicology assessment), documented abuse history from police, medical and family reports as well as physical signs of heroin abuse (needle track marks). For opiatedependent subjects, the only other substance of positive use was alcohol (23%); for controls, alcohol (15%). Of these, 53 specimens were used for brain expression analyses (see Drakenberg et al. 5 ): controls, 16 men, 3 women, average age 34.2±12.4 years, average brain pH 6.72±0.05; heroin, 30 men, 4 women, average age 27±5.3, average brain pH 6.55±0.04.
The second collection consisted of specimens from documented opiate overdose subjects and drug-free control subjects obtained at autopsy (within 20 h of death) as previously described, [19] [20] [21] which were approved by Wayne State University's Human Investigation Committee. Briefly, medico-legal investigations were conducted by forensic pathologists, with manner and cause of death determined after evaluating the circumstances of death, blood and urine toxicology, available police reports, medical records and autopsy results. For opiate-dependent individuals, toxicology revealed use of cocaine (50%) and alcohol (16%). We studied 164 subjects: 114 controls (108 men, 6 women; average age 32.7 ± 10.6) and 50 opioid individuals (44 men, 6 women; average age 33.9 ± 6.9). In all, 56% of the population was African American, and 43% Caucasian. See Supplementary  Table 1 for full population information.
The third collection consisted of 197 subjects obtained from the 'Manhattan HIV Brain Bank' longitudinal clinical cohort. DSM-IV diagnoses of opiate dependence were obtained by administration of the Psychiatric Research Interview for Substance and Mental Disorders. 22 This semistructured interview allows thorough elucidation of alcohol and substance consumption patterns from initial use. In addition, urine toxicology for illicit substances were performed at 6-month intervals; subjects who did not self-report dependence, but chronically displayed positive urine toxicology for illicit opiates were considered dependent. Controls were individuals with no DSM-IV opiate dependency and negative toxicology for illicit opiates. For opiate dependents, other substances included cocaine (72%), cannabis (32%) and alcohol (60%); for controls, alcohol (21%). We studied 88 controls (52 men, 36 women; average age 44.4±9.5) and 109 opiate addicts (61 men, 48 women; average age 44.3±6.8). Race and ethnicity were determined by self-report; for the purposes of this study, Hispanics self-identifying as Black were characterized as African American, and those identifying as White were characterized as Caucasian. Racially, 48% of the population was African American and 45% Caucasian. See Supplementary Table 2 for full population information.
Genotyping
DNA was purified from cerebellar tissue or peripheral blood lymphocytes with DNeasy columns (Qiagen, Valencia, CA, USA). All single-nucleotide polymorphism (SNP) assays were obtained as Taqman Assays-On-Demand (Applied Biosystems, Foster City, CA, USA) and genotyping was performed according to the manufacturer's protocol. Genotype was determined in triplicate using an ABI 7900HT available in the Mount Sinai Quantitative PCR Shared Resource Facility.
Five DRD1 (rs4532, rs686, rs265978, rs265975 and rs265973), three HOMER1 (rs4323213, rs13356332 and rs4293896) and three DLG4 (rs2521985, rs507506 and rs2242449) SNPs were selected for genotyping. All of the selected SNPs were either functional, in strong linkage disequilibrium with a functional polymorphism, or were previously associated with addiction-related phenotypes. [23] [24] [25] [26] [27] [28] See Supplementary Table 3 for a list of all SNPs genotyped, including SNP location, alleles and minor allele frequency.
Gene expression DRD1, HOMER1 and DLG4 riboprobes were synthesized from a human complementary DNA library using nested PCR as described previously. 20, 29 In situ hybridization was performed as previously described. 5, 30 To quantify levels of DRD1, HOMER1 and DLG4 gene expression in putamen and cingulate brain punches, complementary DNA was synthesized (Quanta BioSciences, Gaithersburg, MD, USA) and subjected to real-time PCR analysis using Taqman-based probes (Applied Biosystems); all primers and probes were products of Assays-On-Demand from Applied Biosystems (DRD1, Hs00377719_g1; HOMER1, Hs00188676_m1; DLG4, Hs00176354_m1). Real-time PCR and subsequent analysis were performed with a Roche LightCycler 480 Real-Time PCR system (Roche Applied Science, Indianapolis, IN, USA). Quantification of target gene expression in all samples, performed in triplicate, was normalized to 18S ribosomal RNA (4319413E; Applied Biosystems) using the DDC T method. 31 
Protein expression
Tissue samples were sonicated in sodium dodecyl sulfate extraction buffer. Extracts were aliquoted and kept at À 80 1C until usage. Protein concentration was determined using the bicinchoninic acid protein assay (Fisher, Rockford, IL, USA). Rabbit polyclonal antibody against HOMER1b/c (Abcam, Cambridge, MA, USA) was used. Membranes were washed three times for 15 min in phosphate buffered saline tween-20 buffer and incubated with goat anti-rabbit secondary antibody (LI-COR, Lincoln, NE, USA) for 1 h at room temperature. MemCode membrane staining (Fisher) was used to control for total protein content. Membranes were developed with the LI-COR detection system and the ImageJ software (NIMH, Bethesda, MD, USA) was used for densitometric analysis.
In situ hybridization image analysis
Optical density values were measured using Scion Image for Windows (Scion, Fredrick, MD, USA) from digitalized images with a resolution of 300 d.p.i. (films scanned by Microtek ScanMaker III, Dü sseldorf, Germany) or FLA3000 (FUJIFILM, Stamford, CT, USA). The optical density values were converted to disintegrations per min mg À 1 by reference to co-exposed 14 C standards (American Radiolabeled Chemicals, St Louis, MO, USA). Measurements were taken within striatal subregions (caudate, putamen, nucleus accumbens (NAc) core and shell) aided by published atlas of the primate striatum. 32 Disintegrations per min mg À 1 values from duplicate slides were averaged and used for statistical calculations.
Statistical analysis
The PLINK 1.07 genetic association analysis program 33 was used to verify SNP data quality, test for departure from Hardy-Weinberg equilibrium, test individual SNPs for statistical association, perform multiple correction testing (Bonferroni) and analyze pairwise combinations of SNPs. General linear stepwise regression analysis was used to evaluate genotype group differences with covariates: for example, age, sex, postmortem interval, brain pH and toxicology. Post hoc analysis regarding genotype was performed by using Fisher's least-squares difference test. Significance was set at Po0.05 and trends considered for Po0.10. Statistical evaluations were carried out using JMP (SAS Institute, Cary, NC, USA) software package.
RESULTS
Polymorphisms of DRD1, DLG4 and HOMER1 are associated with opiate abuse Using our combined population (N ¼ 489; 248 controls, 241 opioid abusers, see Supplementary Table 4 for demographics), we genotyped 11 SNPs within DRD1, HOMER1 and DLG4 (see Supplementary Table 3 for list of SNPs tested), and evaluated their association with opiate use. We found significant association for one DRD1 SNP (rs686), one DLG4 SNP (rs507506) and one HOMER1 SNP (rs4323213) with opiate use (Po0.05, Table 1 ). When Caucasians and African Americans were examined separately, we found significant associations for two DRD1 SNPs (rs265975 and rs265973) and two DLG4 SNPs (rs2521985 and rs507506) in the Caucasian population (N ¼ 286, 128 controls and 158 opioid abusers), and a significant association for one DRD1 SNP (rs686) in the African-American population (N ¼ 187, 113 controls and 74 opioid abusers; Po0.05, Table 1 ). A trend for association in HOMER1 (rs4323213, P ¼ 0.081) was also seen in African Americans. Thus, associations for DRD1 and postsynaptic glutamatergic genes with opioid use/abuse were seen within each race although the individual SNPs that were implicated differed.
To account for multiple SNPs tested, Bonferroni corrections were performed on association results. The most significant DLG4 SNP (rs507506) remained statistically significant after correction (P ¼ 0.0016). Following correction in the Caucasian population, two DLG4 SNPs were significant (rs2521985, P ¼ 0.016; rs507506, P ¼ 0.03), whereas a trend for an association was observed for a DRD1 SNP (rs265975, P ¼ 0.09). No significant associations remained after correction in the African-American population.
Interactions between DRD1 and glutamatergic markers To examine potential gene-gene interactions, we examined pairwise combinations of SNPs. Several significant interactions were detected ( Table 2 ). The most significant interaction occurred between rs4293896 of HOMER1 and rs265973 of DRD1 (odds ratio ¼ 0.5524, P ¼ 0.007), but neither of these markers were significant at the single locus level suggesting that the combination of these two SNPs had a role in disease risk together, rather than alone. This interaction appeared to be driven by the Caucasian subjects, however, given that when the cohort was separated along racial categories, this interaction was only significant in Caucasians (odds ratio ¼ 0.5263, P ¼ 0.044) but not in African Americans (odds ratio ¼ 0.6305, P ¼ 0.178; Table 2 ).
Downregulation of mRNA levels in heroin abusers
To investigate the neurobiological implications of genetic associations and interactions, mRNA levels of DRD1, DLG4 and HOMER1 were examined throughout the striatum by in situ hybridization histochemistry (ISHH) in a subset of specimens from the Caucasian European heroin postmortem collection (34 heroin and 19 control subjects). Of the glutamatergic markers, heroin subjects had decreased mRNA expression of DLG4 (P ¼ 0.028) and HOMER1 (P ¼ 0.006) in the putamen (Table 3) , when compared with controls. A similar decrease of the HOMER1 mRNA levels was also detected in the caudate nucleus (P ¼ 0.030) as well as the NAc core (P ¼ 0.001) and shell (P ¼ 0.019). DRD1 mRNA was significantly decreased in the putamen of heroin abusers (P ¼ 0.008; Table 3 ). A similar decrease of DRD1 mRNA was also observed in the NAc shell (P ¼ 0.033) of heroin subjects. Urine morphine concentrations were correlated with HOMER1 mRNA expression levels in the caudate nucleus (r ¼ 0.459, P ¼ 0.018) and putamen (r ¼ 0.476, P ¼ 0.018); similar trend in the NAc. In addition, urine morphine concentration was positively correlated with DLG4 expression in the NAc shell (r ¼ 0.6959, P ¼ 0.001) and core (r ¼ 0.5376 P ¼ 0.017).
Polymorphisms of DRD1 and DLG4 are associated with their respective gene expression in the human striatum To assess the potential neurobiological relevance of the two most significantly associated SNPs with heroin abuse in the Caucasian population, we examined the relationship of rs265975 of DRD1 and rs2521985 of DLG4 to their respective striatal gene expression levels. DRD1 mRNA expression differed in the control group depending on genotype such that control subjects homozygous for the C/T genotype of rs265975 had significantly higher levels of DRD1 mRNA expression than C/C individuals (Po0.05, Figure 1a) . The genotype dose effect was, however, absent in heroin subjects, showing similar levels irrespective of their DRD1 genotype with mRNA expression lower compared with C/T controls (Po0.01, Figure 1a ). For DLG4 mRNA expression, control subjects homozygous for the C/C genotype at rs2521985 had the highest levels of DLG4 mRNA expression as compared with control C/T subjects (Po0.05, Figure 1b) as well as heroin subjects of all genotypes Figure 1b) . Similar to the effects observed for DRD1 genotype in heroin subjects, heroin blunted the normal DLG4 genotype-dependent differences in DLG4 expression apparent in controls (Figure 1b) . For both genes, these genotype effects on gene expression were also found in the caudate region of the striatum (data not shown).
Polymorphisms of DRD1 and HOMER1 are associated with HOMER1b/c protein in the human striatum Given our hypotheses of DRD1 and glutamatergic interactions and to understand the role by which genetic variation may be having in disease risk, we examined the relationship between the DRD1 rs265973 and HOMER1b/c protein levels in putamen as this was the most significant gene-gene interaction observed ( Table 2 ). The allelic frequencies for rs265973 were similar in this subset and the full population (P ¼ 0.23 and 0.73 for controls and heroin subjects, respectively). Although there was not an overall difference between Homer1b/c levels in control and heroin groups (Figure 2a ), a differential pattern was observed between rs265973 DRD1 and HOMER1b/c protein levels depending on the disease grouping, such that in control subjects, individuals with the C/C genotype at rs265973 had the highest levels of HOMER1b/c protein expression (Figure 2b ). In contrast, individuals with the T/T genotype had the lowest levels of HOMER1b/c protein level (Figure 2b ). This dose-dependent pattern was completely reversed in heroin subjects with T/T subjects having the greatest level of HOMER1b/c protein level (Po0.01, Figure 2b ). These effects were specific to the striatum as the DRD1 rs265973 was not significantly related to HOMER1b/c protein or mRNA expression levels measured in either the amygdala or cingulate cortex (data not shown). Also, toxicology did not affect protein expression as none of the heroin metabolites had a significant effect on HOMER1b/c expression.
DISCUSSION
Dysregulation between dopamine and glutamate neural systems is a central hypothesis of addiction disorders. Balanced dopamine-glutamate interaction is mediated through several functional interactions, including a physical interaction between DLG4 and DRD1 within the postsynaptic density to regulate DRD1 trafficking. 12 Interestingly, by studying three separate populations of opiate abusers, we found that polymorphisms of DRD1, DLG4 and HOMER1 were associated with opiate abuse. Also, a strong gene-gene interaction between HOMER1 and DRD1 with heroin abuse was revealed, whose demonstration was limited to Caucasian populations, highlighting a disturbance of interactions between glutamatergic and DRD1 pathways. Such interactions were also evident on the functional level given the differential DRD1 genotype dose relationship to HOMER1 expression in the striatum of control and heroin subjects. Despite the known functional links between glutamate and dopamine, no association study has previously examined the interaction of glutamatergic and dopaminergic variants in addiction populations. Individual SNPs related to dopamine transmission have been most frequently investigated given the critical role of dopamine in reward-related behaviors and that Reward Deficiency Syndrome is characteristic of various addiction disorders. [34] [35] [36] DRD1 variants have been associated with heroin, alcohol and nicotine abuse, [23] [24] [25] and our results confirm this association. Of the other dopaminergic receptors, most attention to date has focused on the dopamine D2 receptor (DRD2), which is central to reward and emotional processing, and some studies have reported an association between genetic variants of DRD2 with heroin dependence or craving. [37] [38] [39] The dopamine D4 receptor has also been positively associated with heroin abuse, [40] [41] [42] [43] but studies of dopamine D3 or dopamine D5 receptor have been less fruitful. 37, 44, 45 Of the two studies that have assessed HOMER1 and addiction disorders, one reported significant association with HOMER1 and cocaine dependence, 27 whereas the other failed to find any association with alcoholism. 28 To date, no investigation has examined HOMER1 and heroin dependence and no studies have examined the role of DLG4 and addiction. Thus, this study adds to the existing literature and moreover highlights the need of further exploring genetic variants related to the postsynaptic density and glutamate transmission in drug dependence.
The strong interactions of HOMER1 and DRD1 in heroin abusers are intriguing given their neurobiological and chromosomal connections. HOMER1 and DRD1 are located on chromosome 5 (5q14 and 5q35, respectively), raising the possibility of a potential physical interaction between these two genes. Unfortunately, the technical strategies such as chromosome confirmation capture assays are not yet optimized to evaluate such physical interactions in human subjects and await future technological advances. Another rationale to account for the strong interaction between HOMER1 and DRD1 may relate to their neuroanatomical organization. Both proteins are highly expressed in the striatum, neocortex and amygdala, brain regions relevant to various aspects of addiction vulnerability including reward, goal-directed behavior, decision making and craving. Of these regions, we only detected a significant interaction between rs265973 of DRD1 and HOMER1 levels in the striatum. In fact, without consideration of the DRD1 genotype, one would have concluded a lack of significant difference of HOMER1b/c levels between heroin abusers and controls. Instead, there was a clear inverse relationship as heroin subjects with the T/T genotype at rs265973 of DRD1 had the highest levels of HOMER1b/c expression, whereas control subjects with this genotype had the lowest expression. It is important to note that we also recently observed dysfunction of HOMER1b/c and DLG4 in the amygdala of heroin abusers. 20 HOMER1b/c amygdala levels were increased in drug abusers, but unrelated to genotype in contrast to the striatal findings. The association of DRD1 primarily with striatal HOMER1b/c levels is in line with the well-documented modulatory role that dopamine exerts at excitatory synapses in the striatum critical for addiction-related behaviors. 46, 47 Several limitations should be considered for our study. One relates to polysubstance use, a common confound for most addition studies. Although we focused on the major substance of abuse in these subjects, opiates, some individuals also had evidence of other substance use, particularly in the Manhattan cohort. However, the European population was predominantly heroin abusers, and opiate was the drug common in each cohort studied. It is nevertheless important to emphasize that neurobiological disturbances of dopamine-glutamate interactions is expected to be a core feature of addictive behaviors in general, 48 so the current findings may extend to other drugs of abuse and addiction-related phenotypes such as reward sensitivity, inhibitory control, and so on. Another limitation relates to the lifetime drugfree status or unknown Reward Deficiency Syndrome in control subjects. Although it is not possible in postmortem populations to rule out potential previous drug use or other addictive behavior in their lifetime, psychiatric interviews were conducted in the Manhattan population. As such, we were able to ascertain these patterns, and only alcohol use was evident in some control subjects. Although undocumented addictive phenotype in controls is an important consideration, significant psychopathology in the control group would have limited the possibility to detect associations and gene-gene interactions with opiate abuse, but and as evidenced, this was not the case. Finally, there may be population stratification, as we examined multiple populations, and each was of relatively small sample size and of different ethnic and racial composition. Despite these limitations, our a priori study design allowed us significant power to detect the gene-gene association with heroin abuse.
Although a strength of postmortem studies is the ability to examine molecular events directly in the human brain, thorough knowledge of the subject such as drug history is limited. Toxicological data were, however, informative showing that morphine urine concentrations at death tended to be positively correlated with HOMER1 (most striatal subregions) and DLG4 (NAc) mRNA expression. The fact that these genes were reduced in heroin subjects suggests even lower expression in the nonintoxicated state. Interestingly, decreased striatal Homer1 49, 50 or Dlg4 18 expression in animal models is associated with behavioral sensitization, which would be predictive of addiction vulnerability.
In summary, we have shown specific disturbances in the glutamatergic postsynaptic density and DRD1 in human heroin abusers in diverse populations. We observe gene-gene interactions between SNPs in these neuronal systems, including a highly significant HOMER1 Â DRD1 interaction. This interaction relates significantly to protein expression of HOMER1 in the dorsal striatum, a brain region implicated in habit formation. Future studies will explore the functional role of these DRD1-glutamate interactions in the opiate abuser as well as examine this interaction in other substance abuse populations.
